Michelle L. O'DOnoghue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michelle L. O'DOnoghue has a total of 539 co-authors. Here are the top co-authors by number of shared publications:
- Marc S. Sabatine
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
22 shared publications Eugene Braunwald
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
18 shared publicationsMarc S. Sabatine
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
15 shared publicationsSabina A. Murphy
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
15 shared publicationsChristopher P. Cannon
Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
11 shared publications- Robert Patrick Giugliano
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
11 shared publications
Latest Publications
- 7 November 2026
- Published by Wolters Kluwer Health in Circulation
Clear Target, Multiple Paths: Rethinking Intensive LDL-C Lowering
- 7 November 2026
- Published by Wolters Kluwer Health in Circulation
Clear Target, Multiple Paths: Rethinking Intensive LDL-C Lowering
- 3 November 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (18) , 1753-1754
A Lasting Legacy: Honoring the Life and Impact of Dr Eugene Braunwald
- 3 November 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (18) , 1753-1754
A Lasting Legacy: Honoring the Life and Impact of Dr Eugene Braunwald
- Open Access
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Lipoprotein (a) Concentrations Across a Global Cross‐Sectional Registry of Patients With Established Coronary Artery Disease
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Open AccessLipoprotein (a) Concentrations Across a Global Cross‐Sectional Registry of Patients With Established Coronary Artery Disease
- 23 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (25) , 1960-1968
Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial
BACKGROUND: Lp(a) (lipoprotein[a]) is a risk factor for coronary heart disease. Whether baseline Lp(a) identifies higher-risk patients who derive more benefit from evolocumab is not established in a population without previous myocardial infarction (MI) or stroke. METHODS: From June 2019 to November 2021, the VESALIUS-CV trial (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarctions or Stroke) enrolled patients with qualifying atherosclerosis or high-risk diabetes without previous MI or stroke and randomized them to evolocumab or placebo (median follow-up 4.6 years). In a prespecified analysis, Lp(a) was assessed at baseline in 7557 patients. Cox models were used to assess the adjusted risk of cardiovascular events by baseline Lp(a) in the placebo arm, and the efficacy of evolocumab by baseline Lp(a). The primary outcome of interest was the composite of major coronary events (coronary heart disease death, MI, or urgent coronary revascularization). RESULTS: Median age was 66 [interquartile range, 60–71] years, and 42.8% were women; median Lp(a) was 28 [interquartile range, 9–132] nmol/L. Higher baseline Lp(a) was associated with an increased risk of major coronary events (adjusted hazard ratio [HR adjusted ] per 100 nmol/L increase in Lp(a), 1.15 [95% CI, 1.05–1.26]; P =0.004), particularly for MI (HR adjusted , 1.23 [95% CI, 1.10–1.38]; P 105 nmol/L versus 61.1 mg/dL and 6.0 nmol/L in those with baseline Lp(a) ≤105 nmol/L. The relative reductions in the rate of major coronary events were 41% (HR, 0.59 [95% CI, 0.41–0.83]) in those with Lp(a) >105 nmol/L compared with 35% (HR, 0.65 [95% CI, 0.51–0.82]) in those below ( P -interaction=0.45 for Lp[a] modeled as continuous variable). The corresponding absolute reductions were 3.7% versus 2.5% ( P -interaction=0.09), corresponding to a number needed to treat of 28 versus 40 to prevent 1 major coronary event at 5 years. CONCLUSIONS: In patients with atherosclerosis or high-risk diabetes but without previous MI or stroke, Lp(a) was independently associated with an increased risk of major coronary events but not ischemic stroke. Evolocumab reduced the relative risk of major coronary events to a similar degree irrespective of baseline Lp(a), with a numerically greater absolute risk reduction in patients with elevated Lp(a). REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03872401.
- 23 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (25) , 1960-1968
Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial
BACKGROUND: Lp(a) (lipoprotein[a]) is a risk factor for coronary heart disease. Whether baseline Lp(a) identifies higher-risk patients who derive more benefit from evolocumab is not established in a population without previous myocardial infarction (MI) or stroke. METHODS: From June 2019 to November 2021, the VESALIUS-CV trial (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarctions or Stroke) enrolled patients with qualifying atherosclerosis or high-risk diabetes without previous MI or stroke and randomized them to evolocumab or placebo (median follow-up 4.6 years). In a prespecified analysis, Lp(a) was assessed at baseline in 7557 patients. Cox models were used to assess the adjusted risk of cardiovascular events by baseline Lp(a) in the placebo arm, and the efficacy of evolocumab by baseline Lp(a). The primary outcome of interest was the composite of major coronary events (coronary heart disease death, MI, or urgent coronary revascularization). RESULTS: Median age was 66 [interquartile range, 60–71] years, and 42.8% were women; median Lp(a) was 28 [interquartile range, 9–132] nmol/L. Higher baseline Lp(a) was associated with an increased risk of major coronary events (adjusted hazard ratio [HR adjusted ] per 100 nmol/L increase in Lp(a), 1.15 [95% CI, 1.05–1.26]; P =0.004), particularly for MI (HR adjusted , 1.23 [95% CI, 1.10–1.38]; P 105 nmol/L versus 61.1 mg/dL and 6.0 nmol/L in those with baseline Lp(a) ≤105 nmol/L. The relative reductions in the rate of major coronary events were 41% (HR, 0.59 [95% CI, 0.41–0.83]) in those with Lp(a) >105 nmol/L compared with 35% (HR, 0.65 [95% CI, 0.51–0.82]) in those below ( P -interaction=0.45 for Lp[a] modeled as continuous variable). The corresponding absolute reductions were 3.7% versus 2.5% ( P -interaction=0.09), corresponding to a number needed to treat of 28 versus 40 to prevent 1 major coronary event at 5 years. CONCLUSIONS: In patients with atherosclerosis or high-risk diabetes but without previous MI or stroke, Lp(a) was independently associated with an increased risk of major coronary events but not ischemic stroke. Evolocumab reduced the relative risk of major coronary events to a similar degree irrespective of baseline Lp(a), with a numerically greater absolute risk reduction in patients with elevated Lp(a). REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03872401.
- 3 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (40) , 6039-6047
Safety of low lipoprotein(a) levels: the FOURIER trial
Background and Aims: Lipoprotein(a) (Lp(a)) is considered a causal risk factor for atherogenesis. A higher prevalence of certain adverse events, including diabetes mellitus (DM), has been reported for patients with low Lp(a) concentrations. Therapeutics that lower Lp(a) are now in clinical testing. Thus, the association between lower Lp(a) concentration and safety outcomes is of clinical importance. Methods: The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized 27 564 patients with stable atherosclerotic cardiovascular disease (ASCVD) to evolocumab versus placebo on a background of statin therapy. The relationship between Lp(a) and the risk of prevalent and incident adverse outcomes of interest was examined, adjusting for relevant predictors. Results: Lp(a) was assessed in 25 090 participants at baseline (median 37 nmol/L, interquartile range 13–165). There was no association between Lp(a) concentration and incident risk of haemorrhagic stroke, serious bleeding, neurocognitive events, malignancy, or atrial fibrillation, including those with Lp(a) levels ≤13 nmol/L. There was an inverse association between lower baseline Lp(a) levels and prevalent DM at baseline (adjusted odds ratio 1.03, 95% confidence interval [CI] 1.02–1.04, P < .001; for every 50 nmol/L lower Lp(a)), as well as the incident risk of developing DM during follow-up (adjusted hazard ratio [HR] 1.05, 95% CI 1.02–1.08, P = .002; for every 50 nmol/L lower Lp(a)), with consistent results by treatment arm. Evolocumab did not increase the risk of DM irrespective of baseline Lp(a), even in participants in the top decile of baseline Lp(a) (adjusted HR .72, 95% CI .38–1.35) in whom evolocumab reduced Lp(a) by a median of 71 nmol/L. Conclusions: In patients with ASCVD, low Lp(a) concentration was not associated with an increased risk of most adverse safety outcomes, but lower Lp(a) was associated with an increased risk of prevalent and incident DM.
- 3 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (40) , 6039-6047
Safety of low lipoprotein(a) levels: the FOURIER trial
Background and Aims: Lipoprotein(a) (Lp(a)) is considered a causal risk factor for atherogenesis. A higher prevalence of certain adverse events, including diabetes mellitus (DM), has been reported for patients with low Lp(a) concentrations. Therapeutics that lower Lp(a) are now in clinical testing. Thus, the association between lower Lp(a) concentration and safety outcomes is of clinical importance. Methods: The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized 27 564 patients with stable atherosclerotic cardiovascular disease (ASCVD) to evolocumab versus placebo on a background of statin therapy. The relationship between Lp(a) and the risk of prevalent and incident adverse outcomes of interest was examined, adjusting for relevant predictors. Results: Lp(a) was assessed in 25 090 participants at baseline (median 37 nmol/L, interquartile range 13–165). There was no association between Lp(a) concentration and incident risk of haemorrhagic stroke, serious bleeding, neurocognitive events, malignancy, or atrial fibrillation, including those with Lp(a) levels ≤13 nmol/L. There was an inverse association between lower baseline Lp(a) levels and prevalent DM at baseline (adjusted odds ratio 1.03, 95% confidence interval [CI] 1.02–1.04, P < .001; for every 50 nmol/L lower Lp(a)), as well as the incident risk of developing DM during follow-up (adjusted hazard ratio [HR] 1.05, 95% CI 1.02–1.08, P = .002; for every 50 nmol/L lower Lp(a)), with consistent results by treatment arm. Evolocumab did not increase the risk of DM irrespective of baseline Lp(a), even in participants in the top decile of baseline Lp(a) (adjusted HR .72, 95% CI .38–1.35) in whom evolocumab reduced Lp(a) by a median of 71 nmol/L. Conclusions: In patients with ASCVD, low Lp(a) concentration was not associated with an increased risk of most adverse safety outcomes, but lower Lp(a) was associated with an increased risk of prevalent and incident DM.
- 12 May 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (19) , 1516-1519
Early Versus Late Initiation of Evolocumab and Arterial Aneurysm Events: An Analysis of FOURIER and FOURIER-OLE
- 12 May 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (19) , 1516-1519
Early Versus Late Initiation of Evolocumab and Arterial Aneurysm Events: An Analysis of FOURIER and FOURIER-OLE
- 30 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (6) , 662-665
The year in cardiovascular medicine 2025: the top 10 papers in thrombosis and antithrombotic therapy
- 30 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (6) , 662-665
The year in cardiovascular medicine 2025: the top 10 papers in thrombosis and antithrombotic therapy
- Top Cited Papers
- 13 January 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (2) , 86-93
Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke
BACKGROUND: Patients with previous ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular events. The benefits of achieving very low levels of low-density lipoprotein cholesterol (LDL-C) in such patients is unclear. METHODS: We analyzed patients with previous ischemic stroke enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), a randomized placebo-controlled trial studying evolocumab in patients with stable atherosclerotic cardiovascular disease (median follow-up, 2.2 years), and through the open-label extension (FOURIER-OLE) period (additional median follow-up, 5 years), to examine the relationship between achieved LDL-C and the long-term incidence of the primary end point (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization) and stroke-related end points. RESULTS: The analysis included 5291 patients with previous ischemic stroke (>4 weeks). Of these, 666 (12.6%), 1410 (26.6%), 586 (11.1%), 508 (9.6%), and 2121 (40.1%) patients achieved LDL-C values of P trend P trend =0.85). CONCLUSIONS: In patients with previous ischemic stroke, it appeared that the lower the LDL-C, down to levels <40 mg/dL, the lower the risk of major adverse cardiovascular events, including recurrent stroke, without a clear increase in risk of hemorrhagic stroke. These findings support the concept that more intensive LDL-C lowering in patients with previous ischemic stroke may be warranted. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01764633/NCT01764633.
- 13 January 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (2) , 86-93
Top Cited PapersEfficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke
BACKGROUND: Patients with previous ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular events. The benefits of achieving very low levels of low-density lipoprotein cholesterol (LDL-C) in such patients is unclear. METHODS: We analyzed patients with previous ischemic stroke enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), a randomized placebo-controlled trial studying evolocumab in patients with stable atherosclerotic cardiovascular disease (median follow-up, 2.2 years), and through the open-label extension (FOURIER-OLE) period (additional median follow-up, 5 years), to examine the relationship between achieved LDL-C and the long-term incidence of the primary end point (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization) and stroke-related end points. RESULTS: The analysis included 5291 patients with previous ischemic stroke (>4 weeks). Of these, 666 (12.6%), 1410 (26.6%), 586 (11.1%), 508 (9.6%), and 2121 (40.1%) patients achieved LDL-C values of P trend P trend =0.85). CONCLUSIONS: In patients with previous ischemic stroke, it appeared that the lower the LDL-C, down to levels <40 mg/dL, the lower the risk of major adverse cardiovascular events, including recurrent stroke, without a clear increase in risk of hemorrhagic stroke. These findings support the concept that more intensive LDL-C lowering in patients with previous ischemic stroke may be warranted. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01764633/NCT01764633.